A rising tide swamps all boats.
The Wall Street Journal this morning is the first to report that the Trump Administration is Weighing Major Cuts to Funding for Domestic HIV Prevention.
"The cuts [in HIV prevention] could affect drugmakers like Gilead Sciences and ViiV Healthcare, which sell HIV/AIDS medicines. Gilead stock dropped nearly 3% in after-hours…
Keep reading with a 7-day free trial
Subscribe to Hardcore Zen to keep reading this post and get 7 days of free access to the full post archives.